Abstract

Drug-Eluting Stents versus Coated Stents in Diabetic Patients with Acute Coronary Syndrome

Background: The term Acute Coronary Syndrome (ACS) is a term that describes the acute phase of ischemic coronary artery disease whether myocardial cell necrosis happens or not. Objective: To compare coated stents and drug-eluting stents in terms of Major Adverse Cardiac Events (MACE) and Instent Restenosis (ISR) rate. Patients and methods: A prospective, comparative, controlled, single-center study was conducted on forty diabetic patients diagnosed as NSTE-ACS with TIMI risk score ≥ 3, whose coronary angiography showed de novo CAD with ≥ 70% luminal stenosis to assess the influence of coated stent on the incidence of MACE and ISR after PCI in comparison with Drug-Eluting Stents (DES) in high-risk patients with ACS. Patients were divided into 2 groups according to the type of the stent; coated stent (titan 2) for group (A) and DES (Xience) for the group (B). MACE was reported during the hospital stay and after 6 months. Results: The incidence of in-hospital MACE showed no statistical significant difference between both groups, however, there was a statistically significant difference between both groups as regards the incidence of follow up MACE at 6 months mainly due to significantly higher incidence of the need for Target Lesion Revascularization (TLR) in the coated stents group. Conclusion: DES is superior to coated stents in patients with NSTE-ACS.

• Full-Text
• PDF